Willd water extract in chronic obstructive pulmonary disease

By: Yiming An · Xiao Yu · Chao Wang · Xin Yu · Jingtong Zheng · Hongqiang Lin

11 December 2025 at 19:00

Front Microbiol. 2025 Nov 25;16:1703853. doi: 10.3389/fmicb.2025.1703853. eCollection 2025.

ABSTRACT

BACKGROUND: Polygala tenuifolia Willd (PT) is a plant with both medicinal and edible values. Traditionally, it has been used for sedation, enhancing cognition, resolving phlegm, and relieving cough. However, its protective effects and mechanisms against chronic obstructive pulmonary disease (COPD) remain unclear.

AIM OF THE STUDY: This study aims to observe the protective effects of the water extract of Polygala tenuifolia Willd (WEPT) on COPD, and to preliminarily elucidate its potential therapeutic mechanisms by integrating network pharmacology, molecular docking, multi-omics analysis, and molecular experiments.

METHODS AND MATERIALS: HPLC quantified WEPT constituents. COPD mice models established via chronic smoke exposure underwent WEPT treatment, and the therapeutic effect was evaluated by lung function test, histopathology and cytokine profiling. Integrated multi-omics analyses (network pharmacology, transcriptomics, microbiomics) identified bioactive compounds, therapeutic targets, pathway regulations, and microbiota dynamics. Molecular docking validated compound-target interactions, while immunohistochemical/fluorescence assays confirmed key protein expression in lung tissues.

RESULTS: WEPT administration effectively reduced inflammatory cytokine levels in COPD mice, improved lung function, and alleviated histopathological damage like alveolar structural injury and airway inflammation. Network pharmacology and transcriptomic analyses identified Norhyoscyamine and Onjixanthone I as key active components, targeting PIK3CA and AKT1 via PI3K-AKT pathway regulation. Microbiome analysis showed WEPT restored gut microbiota balance. Molecular docking confirmed strong binding of bioactive compounds to core targets, while immunostaining assays demonstrated WEPT suppressed p-PI3K and p-AKT protein expression.

CONCLUSION: WEPT may exert its intervention effects on COPD through a multi-target and multi-level comprehensive regulatory mechanism.

PMID:41377050 | PMC:PMC12685879 | DOI:10.3389/fmicb.2025.1703853

AI Application in Anti-Money Laundering for Sustainable and Transparent Financial Systems

cs.AI, q-bio.NC updates on arXiv.org

By: Chuanhao Nie · Yunbo Liu · Chao Wang

9 December 2025 at 13:00

arXiv:2512.06240v1 Announce Type: new Abstract: Money laundering and financial fraud remain major threats to global financial stability, costing trillions annually and challenging regulatory oversight. This paper reviews how artificial intelligence (AI) applications can modernize Anti-Money Laundering (AML) workflows by improving detection accuracy, lowering false-positive rates, and reducing the operational burden of manual investigations, thereby supporting more sustainable development. It further highlights future research directions including federated learning for privacy-preserving collaboration, fairness-aware and interpretable AI, reinforcement learning for adaptive defenses, and human-in-the-loop visualization systems to ensure that next-generation AML architectures remain transparent, accountable, and robust. In the final part, the paper proposes an AI-driven KYC application that integrates graph-based retrieval-augmented generation (RAG Graph) with generative models to enhance efficiency, transparency, and decision support in KYC processes related to money-laundering detection. Experimental results show that the RAG-Graph architecture delivers high faithfulness and strong answer relevancy across diverse evaluation settings, thereby enhancing the efficiency and transparency of KYC CDD/EDD workflows and contributing to more sustainable, resource-optimized compliance practices.

Treatment of advanced-stage non-small cell lung cancer: Current progress and a glimpse into the future (Review)

Omics In Lung

By: Zeming Wang · Guoying Cai · Junquan Zhu · Juchao Wang · Yufeng Zhang

31 March 2025 at 18:00

Mol Clin Oncol. 2025 Mar 12;22(5):42. doi: 10.3892/mco.2025.2837. eCollection 2025 May.

ABSTRACT

Before the twentieth century, patients with advanced lung cancer had limited treatment options and chemotherapy was the primary form of treatment, with an overall survival often <0.5 years. However, with advances in society and medical technology, the treatment approaches for advanced non-small cell lung cancer (NSCLC) have markedly changed. Traditional chemotherapy has been gradually replaced by targeted therapy and immunotherapy, leading to the emergence of various new therapeutic options that offer patients more personalized and precise care. This raises the question of what the future holds for the treatment of NSCLC. This review provides a comprehensive analysis of the latest breakthroughs in targeted therapies, immunotherapies, and drugs for antibody-drug conjugates (ADCs), highlights advances in multimodal combination therapy strategies, and explores the causes of resistance and the challenges that exist in overcoming it. In particular, this review provides unique insights into key directions for future research in NSCLC, such as personalised treatment strategies and biomarker exploration based on multi-omics data, aiming to provide new inspiration for clinical decision-making and research.

PMID:40160297 | PMC:PMC11948471 | DOI:10.3892/mco.2025.2837

Reading view